ArticleRMD open2025
Decreased GPR55 expression links B-cell activation and vascular remodelling in atherosclerosis in patients with early rheumatoid arthritis.
Article in RMD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research advances of pan-immune inflammation value in rheumatoid arthritis.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveInflammation and repair responses may be involved in atherosclerosis in rheumatoid arthritis (RA), although mechanisms are unknown. GPR55, a cannabinoid receptor expressed in haematopoietic and stromal tissues, has been implicated in atherosclerosis in mouse models, but evidence in humans is lacking. Our aim was to evaluate GPR55 expression in leucocyte populations in RA and their potential role in atherosclerosis.
methodsGPR55 expression was quantified by flow cytometry in 63 treatment-naïve patients with RA, 11 individuals with arthralgia and 36 controls. Atherosclerosis was assessed by Doppler ultrasound. Cytokines were measured by immunoassays, and serum proteomics were performed by a high-throughput targeted panel. In vitro cultures were performed with mononuclear cells from healthy donors.
resultsDecreased GPR55 expression in B-cells and monocytes was found in RA, whereas no differences were observed in arthralgia. Public datasets validated these findings. B-cell GPR55 expression was unrelated to clinical features, risk factors and atherosclerosis in RA, but exhibited divergent associations with leucocyte populations. GPR55 expression was associated with proinflammatory cytokines, immunoglobulin and antibody levels, metabolomic markers of inflammation and proteomic signatures related to vascular remodelling and B-cell responses in RA. These associations were dependent on the atherosclerosis status. Lipopolysaccharide exposure in vitro decreased GPR55 expression in B-cells in a dose-dependent manner, which overlapped increasing CB86 expression.
conclusionsReduced GPR55 expression hallmarked B-cells and monocyte subsets in early RA. GPR55 expression was linked to B-cell activation-related pathways, presumably via T-cell independent mechanisms and vascular remodelling. GPR55 may be a novel hub between immune circuits and maladaptive responses in atherosclerosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.